Matthew Winton

Insider Reports History

Location
Boston, MA
Signature
/s/ William R. Elder, attorney-in-fact for the Reporting Person
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew Winton:

Form 4 holding COO

Inozyme Pharma, Inc.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
$184,675
Report date
01 Jul 2025
Price
$4.45
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Commercial and Business

CervoMed Inc.

Security class
Common Stock
Shares / value
15,000
Estimated value
$119,250
Report date
18 Nov 2025
Price
$7.95
Ownership
Direct
Form 4 holding Chief Commercial and Business

CervoMed Inc.

Security class
Stock Option (Right to Buy)
Shares / value
30,000
Estimated value
Report date
11 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Matthew Winton

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .